These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28837260)

  • 1. A Selective Biligand Inhibitor of CK2 Increases Caspase-3 Activity in Cancer Cells and Inhibits Platelet Aggregation.
    Rahnel H; Viht K; Lavogina D; Mazina O; Haljasorg T; Enkvist E; Uri A
    ChemMedChem; 2017 Oct; 12(20):1723-1736. PubMed ID: 28837260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.
    Bestgen B; Kufareva I; Seetoh W; Abell C; Hartmann RW; Abagyan R; Le Borgne M; Filhol O; Cochet C; Lomberget T; Engel M
    J Med Chem; 2019 Feb; 62(4):1817-1836. PubMed ID: 30689946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis.
    Wang J; Feng C; He Y; Ding W; Sheng J; Arshad M; Zhang X; Li P
    Oncotarget; 2015 Sep; 6(29):27700-13. PubMed ID: 26172393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
    Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
    J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function.
    Ryu SY; Kim S
    Eur J Pharmacol; 2013 Nov; 720(1-3):391-400. PubMed ID: 24140231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase induced activation and cytoskeletal translocation of protein kinase CK2 in protease activated receptor 1-stimulated platelets.
    Nakanishi K; Toyoda H; Tanaka S; Yamamoto H; Komada Y; Gabazza EC; Hayashi T; Suzuki K; Ido M
    Thromb Res; 2010 Dec; 126(6):511-6. PubMed ID: 21055793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetoxymethyl Ester of Tetrabromobenzimidazole-Peptoid Conjugate for Inhibition of Protein Kinase CK2 in Living Cells.
    Viht K; Saaver S; Vahter J; Enkvist E; Lavogina D; Sinijärv H; Raidaru G; Guerra B; Issinger OG; Uri A
    Bioconjug Chem; 2015 Dec; 26(12):2324-35. PubMed ID: 26559659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.
    Zhao T; Jia H; Li L; Zhang G; Zhao M; Cheng Q; Zheng J; Li D
    Oncol Rep; 2013 Jul; 30(1):377-84. PubMed ID: 23595577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
    Vahter J; Viht K; Uri A; Enkvist E
    Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
    Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
    Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Casein Kinase II: an attractive target for anti-cancer drug design.
    Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
    Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP site-directed inhibitors of protein kinase CK2: an update.
    Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
    Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of catalase and oxidative modification of protein kinase CK2 lead to the failure of apoptosis repressor with caspase recruitment domain to inhibit cardiomyocyte hypertrophy.
    Murtaza I; Wang HX; Feng X; Alenina N; Bader M; Prabhakar BS; Li PF
    J Biol Chem; 2008 Mar; 283(10):5996-6004. PubMed ID: 18171680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
    Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
    Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazole- and selenazole-comprising high-affinity inhibitors possess bright microsecond-scale photoluminescence in complex with protein kinase CK2.
    Vahter J; Viht K; Uri A; Manoharan GB; Enkvist E
    Bioorg Med Chem; 2018 Oct; 26(18):5062-5068. PubMed ID: 30217463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.